Real-World Studies
Incidence, Predictors, and Survival Impact of Acute Kidney Injury Following CAR-T Cell Therapy
Delneste et alJournal of Clinical Medicine

In a retrospective cohort study evaluating 220 adult patients (mean age 63 ± 12 years; mostly treated for B-cell lymphomas) who received chimeric antigen receptor T-cell (CAR-T) therapy at a university hospital between April 2019 and December 2023, the cumulative incidence of acute kidney injury (AKI) was 20.5% (n = 45). AKI occurred early following CAR-T cell infusion, at a mean of 4 ± 3 days. Among patients who developed AKI, 22% experienced KDIGO stage 3 disease, and 15.6% required renal replacement therapy. Baseline pre-existing chronic kidney disease (CKD) was documented in 26% of the overall cohort, and 24% had been admitted to the intensive care unit.
Multivariate analysis showed that pre-existing CKD was strongly associated with AKI occurrence (adjusted odds ratio [aOR] 8.9), as was concurrent exposure to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) alongside nephrotoxic agents (aOR 2.7). In univariate analysis, the severity of cytokine release syndrome (CRS) and CAR-T-associated encephalopathy were also associated with AKI. Furthermore, the development of severe AKI was associated with reduced progression-free survival as well as reduced overall survival.
Key Takeaways
- Acute kidney injury occurred in 20.5% (n = 45) of patients, at a mean of 4 days following CAR-T cell infusion, with 22% classified as KDIGO stage 3 and 15.6% requiring renal replacement therapy.
- Pre-existing chronic kidney disease (adjusted OR 8.9) and co-exposure to ACE inhibitors or ARBs with nephrotoxic agents (adjusted OR 2.7) were identified as independent risk factors for acute kidney injury in multivariate analysis.
- Severe acute kidney injury was associated with reduced progression-free survival and reduced overall survival following CAR-T cell therapy.
Read the original sourceJournal of Clinical Medicine
